Pure Global AI
NCT06129955Not yet recruiting

Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma

A Phase II Clinical Study on the Efficacy and Safety of Pucotenlimab Combined With Lenvatinib as a Neodjuvant Therapy for Non Clear Cell Renal Cell Carcinoma With Indications for Partial Nephrectomy But High Surgical Risk: A Single Arm Approach
Sun Yat-sen UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Renal Cell Carcinoma
Drug/Device/Intervention
Pucotenlimab Combined With Lenvatinib
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou, China
Timeline & enrollment
Phase
Phase 2
Start date
Nov 11, 2023
End date
Dec 31, 2025
Enrollment
47 participants
Primary outcome

ORR

Summary

Through the neoadjuvant treatment with a combination of Pucotenlimab and Lenvatinib, it
 eventually enables the successful and safe implementation of partial nephrectomy in patients
 with localized renal cancer, who have indications for nephron-sparing surgery but face
 significant difficulty in kidney preservation (T1b with an endophytic component ≥75% or T2).

ICD-10 classifications
Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06129955
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06129955 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 47 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.